Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Luciano
Contact Luciano, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome
Conflicts of Interest F.P. reports participation at educational meetings of Sanofi, Sobi, Biomarin, Kedrion and Bayer, and the advisory board of Sanofi, Sobi, Roche, CSL Behring, Novo Nordisk, Biomarin, Regeneron, Metagenomi, Star-Therapeutics, Bayer, Pfizer, Takeda, TargED. A.C. reports participation at educational meetings of Roche and Novo Nordisk, and the advisory board of Bayer. The other authors declare no conflicts of interest.
Effect of the Polymorphic Variant p.D1472H on the Platelet‐Dependent VWF Activity Assays
Background The von Willebrand factor (VWF) p.D1472H variant has been shown to artificially lower ristocetin cofactor (VWF:RCo) levels because of impaired VWF binding to ristocetin. Understanding the variant's effect on platelet-dependent VWF activity assays is crucial for avoiding over- or misdiagnosis of von Willebrand disease. Aim To determine whether p.D1472H affects the VWF:GPIbR latex immunoassay (LIA).
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Luciano
Contact Luciano, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack